| Specification- || pH range- 5.5 to 7.5|
Dactinomycin is a clear, gold-colored liquid given into a vein (IV).
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy.
| Indication : || For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen.|
|Dosage :- || Dose intensity per 2-week cycle for adults or children should not exceed 15 mcg/kg/day or 400-600 mcg/m²/day intravenously for five days.|
|Contra Indications:-|| Active infection with chiken pox or herpes zoster (a severe generalized form of disease may occure), infants less than12 months.|
|Precautions:- || This drug is not recommended for use during pregnancy. Precaution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug, especially the effect on blood cell production (myelosuppression).|
| Drug interaction: || Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. |
| Adverse effects: || Nausea, vomiting, malaise, fatigue, cheilitis, dysphagia, bone marrow depression gastric ulceration, hepatitis, hepatomegaly, abnormal liver function, alopecia, skin eruotion.|
| Storage:|| Powder for injection at room temperature (59° to 86°F). Protect from light and humidity. |